Australia markets closed

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.8006+0.0106 (+1.34%)
At close: 04:00PM EDT
0.8130 +0.01 (+1.55%)
After hours: 06:55PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 122.03M
Enterprise value 263.42M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)297.65
Price/book (mrq)63.84
Enterprise value/revenue 704.33
Enterprise value/EBITDA -2.07

Trading information

Stock price history

Beta (5Y monthly) 1.96
52-week change 3-77.24%
S&P500 52-week change 325.61%
52-week high 33.6700
52-week low 30.5400
50-day moving average 30.9941
200-day moving average 31.0006

Share statistics

Avg vol (3-month) 33.93M
Avg vol (10-day) 31.55M
Shares outstanding 5152.38M
Implied shares outstanding 6152.38M
Float 8120.2M
% held by insiders 15.44%
% held by institutions 145.42%
Shares short (15 Aug 2024) 416.75M
Short ratio (15 Aug 2024) 44.03
Short % of float (15 Aug 2024) 415.44%
Short % of shares outstanding (15 Aug 2024) 411.04%
Shares short (prior month 15 July 2024) 417M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-42,211.23%

Management effectiveness

Return on assets (ttm)-27.10%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)374k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -151.58M
Net income avi to common (ttm)-162.1M
Diluted EPS (ttm)-1.1900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)71.23M
Total cash per share (mrq)0.47
Total debt (mrq)212.62M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.38
Book value per share (mrq)-0.57

Cash flow statement

Operating cash flow (ttm)-181.8M
Levered free cash flow (ttm)-98.53M